(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.03%) $0.926
(-0.05%) $10.84
(-0.13%) $0.791
(-0.09%) $92.49
Live Chart Being Loaded With Signals
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...
Stats | |
---|---|
Today's Volume | 1.83M |
Average Volume | 1.11M |
Market Cap | 36.47M |
EPS | $0 ( 2024-03-26 ) |
Next earnings date | ( $0 ) 2024-05-09 |
Last Dividend | $0.200 ( 2014-03-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.553 |
ATR14 | $0.0510 (4.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-08 | Ra Capital Management, L.p. | Sell | 5 914 252 | Common Stock |
2023-06-08 | Ra Capital Management, L.p. | Sell | 10 000 | Stock Option (Right to Buy) |
2023-06-08 | Ra Capital Management, L.p. | Sell | 20 000 | Stock Option (Right to Buy) |
2023-06-08 | Ra Capital Management, L.p. | Sell | 30 000 | Stock Option (Right to Buy) |
2023-06-06 | O'neil Thomas P. | Sell | 13 877 | Common Stock, $0.0001 par value |
INSIDER POWER |
---|
54.68 |
Last 97 transactions |
Buy: 62 291 817 | Sell: 17 994 879 |
Volume Correlation
Satsuma Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
NRBO | 0.956 |
DLTH | 0.937 |
NXTC | 0.934 |
TFFP | 0.933 |
TOI | 0.93 |
AGLE | 0.923 |
PRTK | 0.923 |
VIAV | 0.917 |
ONCS | 0.914 |
SGRP | 0.914 |
10 Most Negative Correlations | |
---|---|
AGFS | -0.944 |
APEN | -0.938 |
PRDO | -0.932 |
NRIM | -0.92 |
FANH | -0.916 |
VLYPO | -0.916 |
UFPT | -0.916 |
MACK | -0.914 |
TSBK | -0.91 |
AMRB | -0.906 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Satsuma Pharmaceuticals Correlation - Currency/Commodity
Satsuma Pharmaceuticals Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-2.16 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.300 |
Q4 | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.680 |
Q3 | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
Satsuma Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-19 |
Last Dividend | $0.200 | 2014-03-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-04-15 | |
Next Payout Date | N/A | |
# dividends | 7 | -- |
Total Paid Out | $1.500 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.57 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.086 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 1.339 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.44 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.09 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.35 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00267 | -1.500 | 9.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 107.96 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.113 | 2.00 | -0.371 | -0.742 | [0 - 30] |
freeCashFlowPerShareTTM | -1.117 | 2.00 | -0.559 | -1.117 | [0 - 20] |
debtEquityRatioTTM | 0.00308 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -318.09 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.773 | 1.000 | -0.179 | 0 | [1 - 100] |
returnOnEquityTTM | 1.339 | 2.50 | 1.152 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.117 | 2.00 | -0.372 | -1.117 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.113 | 2.00 | -0.371 | -0.742 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00534 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.623 |
Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators